Neuland Laboratories Limited – Investor Presentation Summary

Key Operational Highlights

  • CMS business driven by commercial molecules with growth in new project orders
  • GDS Prime segment key molecules: Ezetimibe and Mirtazapine (Ezetimibe likely growth driver)
  • GDS Specialty business driven by Aripiprazole Sterile, Donepezil and Apixaban
  • Working capital days of sale improved to 84 days in Q1FY27 from 137 days in Q4FY26 due to decrease in receivables
  • Total reactor capacity: 12,26,000 liters across three US FDA and cGMP compliant manufacturing facilities
  • R&D team of 406 people with new 140,000 sq ft R&D center in Hyderabad's Genome Valley

Segment-wise Performance

  • CMS business: Revenues driven by commercial molecules with traction from Innovators with peptides molecules
  • GDS business: Comprises Prime segment (mature APIs) and Specialty/ Niche APIs (complex, high-value products)
  • Prime products historically contributed more than 70% of total GDS business

Financial Highlights

Revenue: Rs. 650.1 crore (Q1FY27)

EBITDA: Rs. 231.1 crore (Q1FY27)

PAT: Rs. 147.4 crore (Q1FY27)

EPS: Rs. 114.9 (Q1FY27)

Margins: EBITDA Margin 35.5%, PAT Margin 22.7% (Q1FY27)

YoY comparison: Revenue up 116.3%, EBITDA up 448.2%, PAT up 975.0% vs Q1FY26

QoQ comparison: Revenue down 17.6%, EBITDA down 27.6%, PAT down 30.6% vs Q4FY26

Drivers of financial performance: Scale up in key molecules in CMS business, operating leverage

Geographical Revenue Split

Not Specified

Balance Sheet Snapshot

Shareholder's Funds: Rs. 2,013.2 crore (Jun-26)

Net Debt: Rs. -308.5 crore (net cash position, Jun-26)

Tangible Assets (including CWIP): Rs. 1,116.9 crore (Jun-26)

Working Capital: Rs. 600.5 crore (Jun-26)

Current Ratio: 2.1x (Mar-26)

Debt to Equity: 0.1x (Mar-26)

Financial Health Insights: Strong net cash position, improved working capital management

Capex & Cash Flow Health

Capital Expenditure: Rs. 122 crore outflow (Q1FY27)

Free Cash Flow: Not Specified

Operating Cash Flow: Not Specified

Net Debt Movement: Improved from -156.8 crore (Mar-26) to -308.5 crore (Jun-26)

Investment Rationale: Capacity expansion for backward integration and new business

Strategic & R&D Initiatives

Investments in Innovation: New state-of-the-art R&D center (140,000 sq ft) in Hyderabad's Genome Valley

Significant R&D achievements: Several NCE APIs added in NDA or commercial stage drugs, support for multiple APIs in Phase 2 and Phase 3

Generic API business: 1010+ DMFs filed, 300+ API processes developed, 204+ patents filed

Chemistry capabilities: Synthetic portion of fermented molecules, Deuterated molecules, Peptides, Carbohydrate chemistry, Organometallic carbon carbon bond formation, Heterocyclic compounds, Chiral compounds manufacturing

Expected impact on growth: Pipeline projects to be delivered over current and next financial years

Strategic Rationale: Building customer confidence and foundation for long-term partnerships

Industry Trends & Business Environment

Not Specified

Management Commentary & Growth Outlook

Strategic Outlook: "Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS businesses and represents a good start to the year. While Commercial Products contributed to most of the revenue, we are seeing exciting developments in terms of the pipeline projects. The depth of customer conversations today is significantly stronger, and we are increasingly engaging on broader capability-led discussions rather than individual projects alone. Internally our focus now is on ensuring that we deliver consistently, build customer confidence and establish the foundation for long-term partnerships. Even as we have invested significantly over the last three years and all our significant Capex projects are proceeding according to plan, I believe the intensity of our investments will further increase based on the opportunities that available to us." - Saharsh Davuluri, CEO & MD

FY Guidance: Not Specified

Market Share Targets: Not Specified

Risks and Opportunities: Not Specified

ESG Updates

Environment Commitments: Reduce Scope 1 & 2 emissions by 58.8% by FY2033-34 (FY2023-24 baseline), Achieve Net Zero by FY2049-50, Reduce Scope 3 emissions by 63.8% by FY2033-34, Achieve 25% water neutrality by FY2034-35 and 100% by FY2049-50, Maintain Zero Liquid Discharge and Zero Waste to Landfill

Social Commitments: Maintain Zero Fatality, Nil Long-term Injury Frequency Rate, Achieve 10% women in management and 16% women hirings by FY2029-30

Governance Commitments: Maintain 100% compliance across GMP operations, Strengthen crisis management, >90% business process digitization by FY29-30, Sustainable Supply Chain roadmap